Patent intelligence · US
US 12097189
Pharmaceutical composition for modified release
Pharmaceutical composition for modified release
Patent details — US 12097189
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 24, 2024
- Expiration
- Sep 19, 2044
- Applicant
- ASTELLAS PHARMA INC [JP]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 16 A I, A61K 9/ 20 A I, A61K 9/ 28 A I
Quick answer
US 12097189 (Pharmaceutical composition for modified release) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS PHARMA INC [JP]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 16 A I, A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 426 A I, A61K 47/ 36 A I
More from ASTELLAS PHARMA INC [JP]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12097189?
US 12097189 (Pharmaceutical composition for modified release) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12097189?
ASTELLAS PHARMA INC [JP] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12097189 expire?
Our index shows an expiration date of Sep 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.